Tag Archives: Vasant Narasimhan

Novartis collaborates with Ionis and Akcea to license two novel treatments to reduce cardiovascular risk in patients with high levels of lipoproteins

Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which is a potent regulator of triglycerides … Read the full press release

New analyses confirm Novartis’ Ultibro® Breezhaler® more effective option for patients at risk of COPD flare-ups

Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients’ need for rescue medication and had improved benefit-risk profile compared to Seretide, with … Read the full press release

Novartis: Xolair helps patients with Chronic Spontaneous Urticaria (CSU) achieve significant improvements in quality of life measures

New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2] Additional data at WCD show the consistent negative health impact and economic burden of CSU, … Read the full press release

Novartis: Cosentyx shows superior efficacy compared to placebo in patients with psoriasis of the palms, soles and nails, all difficult-to-treat locations of plaque psoriasis

Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients with moderate-to-severe palmoplantar psoriasis achieved clear or almost clear skin on their palms and … Read the full press release

Novartis announced positive results from two pivotal Phase III clinical trial programs for QVA149 and NVA237 in patients with COPD

QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderate-to-severe COPD patients[8],[9] In … Read the full press release

Novartis announces new Gilenya® analyses to be presented at the 67th American Academy of Neurology Annual Meeting in Washington, DC, April 18-25, 2015

New analysis will confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity’ (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progression in … Read the full press release

Novartis’ two pivotal Phase III studies of AIN457 (secukinumab) in psoriatic arthritis (PsA) met primary and key secondary endpoints

Secukinumab met primary and key secondary endpoints in two pivotal Phase III studies showing superiority to placebo in patients with adult onset psoriatic arthritis (PsA) PsA is a debilitating, long-lasting condition that causes inflammation of joints and skin and affects … Read the full press release